CytoMed’s in-house manufacturing capability ensures not only the quality and availability of cellular therapies, which are crucial for clinical success but also cost-effective manufacturing, which will be critical for commercial viability. As such, the company has constructed and fully equipped its own comprehensive GMP facility in Johor, Malaysia. Built in 2019, the facility successfully completed manufacturing runs in 2020 and was found to comply with the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (“PIC/S”) in 2021.
The GMP facility also includes a Quality Control lab to support the release of cellular products and a research and development lab to conduct staff training and process development. The facility is ready to support Phase I and II clinical trials.